(Q41556524)

3 October 2017

title

Assessment of minimal residual disease in myeloma and the need for a consensus approach (English)

1 reference

3 October 2017

1

1 reference

Maryalice Stetler-Stevenson

3 October 2017

series ordinal

3

object named as

Maryalice Stetler-Stevenson

1 reference

3 October 2017

Bruno Paiva

2

1 reference

3 October 2017

publication date

22 July 2015

1 reference

Cytometry Part B: Clinical Cytometry

3 October 2017

published in

1 reference

3 October 2017

volume

90

1 reference

3 October 2017

issue

1

1 reference

3 October 2017

page(s)

21-25

1 reference

How should we treat newly diagnosed multiple myeloma patients?

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21272

7 January 2021

Identifiers

DOI

10.1002/CYTO.B.21272

1 reference

3 October 2017

0 references

1 reference